HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism.

AbstractOBJECTIVE:
To compare the clinical efficacy and safety of high-dose (5 mg/day) and low-dose (2.5 mg/day) finasteride in the treatment of hirsutism in women.
DESIGN:
A prospective, randomized and controlled clinical trial.
METHODS:
Fifty-six hirsute women with moderate to severe hirsutism were prospectively evaluated to see the effects of low-dose (2.5 mg/day) and high-dose (5 mg/day) finasteride. Patients were randomly divided into two treatment groups. Group I (n=29) received 2.5 mg finasteride/day and group II (n=27) received 5 mg finasteride/day orally for 1 year. Hirsutism score, body mass index and hormonal parameters (FSH, LH, estradiol, androstenedione, testosterone, free testosterone, 17alpha-hydroxyprogesterone, dehydroepiandrosterone sulfate and sex hormone-binding globulin) were measured in all the patients before treatment and repeated at six-monthly intervals.
RESULTS:
The hirsutism scores decreased significantly at months 6 and 12 from a mean+/-s.d. of 18.4+/-4.6 to 13.3+/-5.2 (P<0.001) and 18.4+/-4.6 to 8.6+/-4.2 (P<0.001) in group I and from 18.7+/-5.2 to 13.9+/-5.3 (P<0.001) and 18.7+/-5.2 to 10.3+/-5.0 (P<0.001) in group II respectively. No significant changes in the blood chemistry and hormonal parameters except estradiol levels were observed. No serious side-effects were seen in the two groups. In group II, estradiol levels increased significantly at 6 and 12 months.
CONCLUSIONS:
In this study, hirsutism scores decreased significantly at 6 and 12 months in both groups I and II. Low-dose (2.5 mg/day) finasteride is safe and cost effective in the treatment of hirsutism and may be used instead of high-dose finasteride (5 mg/day) therapy.
AuthorsFahri Bayram, I Ipek Müderris, Muhammed Güven, Fahrettin Keleştimur
JournalEuropean journal of endocrinology (Eur J Endocrinol) Vol. 147 Issue 4 Pg. 467-71 (Oct 2002) ISSN: 0804-4643 [Print] England
PMID12370107 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Enzyme Inhibitors
  • Sex Hormone-Binding Globulin
  • Testosterone
  • Androstenedione
  • Estradiol
  • Dehydroepiandrosterone Sulfate
  • Finasteride
  • 17-alpha-Hydroxyprogesterone
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
Topics
  • 17-alpha-Hydroxyprogesterone (blood)
  • Adolescent
  • Adult
  • Androstenedione (blood)
  • Dehydroepiandrosterone Sulfate (blood)
  • Enzyme Inhibitors (administration & dosage)
  • Estradiol (blood)
  • Female
  • Finasteride (administration & dosage)
  • Follicle Stimulating Hormone (blood)
  • Hirsutism (blood, drug therapy)
  • Humans
  • Luteinizing Hormone (blood)
  • Sex Hormone-Binding Globulin (metabolism)
  • Testosterone (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: